Methods and devices for connecting nerves

• US 9,931,121 B2
• Filed: 10/16/2012
• Issued: 04/03/2018
• Est. Priority Date: 10/17/2011
• Status: Active Grant

• Current Assignee: University of Utah Research Foundation (State of Utah)
• Original Assignee: University of Utah Research Foundation (State of Utah)
• Inventors: Agarwal, Jayant P., Gale, Bruce Kent, Sant, Himanshu Jayant, Lin, Keng-Min
• Primary Examiner(s): Templeton, Christopher L
• Assistant Examiner(s): Ulsh, George J
• Application Number:
  US14/352,024
• Publication Number:
  US 20140336681A1
• Time in Patent Office: 1,995 Days
• Field of Search: 606152
• CPC Class Codes: A61B 17/1128 of nerves
• CPC Class Codes: A61B 2017/1132 End-to-end connections
• CPC Class Codes: A61F 2/00 Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents as cosmetic articles, see the relevant subclasses, e.g. wigs, hair pieces, A41G3/00, A41G5/00; artificial nails A45D31/00; dental prostheses A61C13/00; materials for prostheses A61L27/00; artificial hearts A61M60/00; artificial kidneys A61M1/14
• CPC Class Codes: A61F 2/0063 Implantable repair or support meshes, e.g. hernia meshes
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 2430/32 for nerve reconstruction
• CPC Class Codes: A61L 27/18 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/3675 Nerve tissue, e.g. brain, spinal cord, nerves, dura mater
• CPC Class Codes: A61L 27/383 Nerve cells, e.g. dendritic cells, Schwann cells
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

A nerve repair conduit configured to be secured on first and second portions of a selected nerve. The nerve repair conduit includes a polymeric body having a proximal end, a distal end, an exterior surface and an interior surface defining an interior lumen. In addition, the nerve conduit includes at least one drug reservoir to hold agent(s) that may, for example, facilitate nerve regeneration. The drugs diffuse from the drug reservoir(s) into the nerve repair conduit through an outlet (e.g., a semipermeable membrane) in proximity to the first and second portions of a selected nerve. The nerve repair conduit may be configured to deliver the agent(s) at a rate having substantially zero-order kinetics and/or at a constant rate over a selected period of time (e.g., at least 1 week).

Claims

1. A nerve repair conduit, comprising:

a polymeric body having a proximal end, a distal end, an exterior surface, and an interior surface which defines an interior lumen, wherein the polymeric body is configured to be secured to a first portion of a nerve and a second portion of a nerve;

one or more drug reservoirs each separately defined by a respective exterior surface directly connected to the exterior surface of the polymeric body, wherein the one or more drug reservoirs are configured to be implanted in vivo and contain at least one agent and optionally an excipient;

wherein the one or more drug reservoirs further comprise one or more dividers forming separate reservoirs for separate agents within the one or more reservoirs, the one or more dividers being oriented orthogonal to a long axis of the nerve repair conduit to form the separate reservoirs at different longitudinal sections of the nerve repair conduit; and

at least one outlet formed between the one or more drug reservoirs, and the interior surface of the polymeric body so as to enable delivery of the at least one agent from the separate reservoirs through the polymeric body to the interior lumen of the polymeric body without requiring degradation of the polymeric body for release of the at least one agent.

2. The nerve repair conduit of claim 1, wherein the nerve repair conduit is configured for covering a damaged portion of a nerve and deliver one or more drugs thereto increase the rate of functional recovery.

3. The nerve repair conduit of claim 2, wherein the damaged portion includes one or more of an injured but intact nerve, a partially transected nerve, or a transected nerve.

4. The nerve repair conduit of claim 1, wherein the at least one outlet is configured to deliver the at least one agent at a rate having substantially zero-order kinetics and over a period of time of at least 1 week.

5. The nerve repair conduit of claim 1, wherein the separate agents have at least one of different release rates, different release times, or different release locations in the interior lumen.

6. The nerve repair conduit of claim 1, wherein the at least one agent includes a neurotrophic factor selected to enhance the rate of nerve regeneration.

7. The nerve repair conduit of claim 6, wherein the neurotrophic factor includes one or more of nerve growth factor (“

NGF”

), glial cell-derived neurotrophic factor (“

GDNF”

), vascular endothelial growth factor (“

VEGF”

), netrin-1, or fibroblast growth factor (“

FGF”

).

8. The nerve repair conduit of claim 1, wherein the at least one agent includes at least one anti-rejection drug.

9. The nerve repair conduit of claim 1, wherein the interior lumen is lined with one or more of Schwann cells, stem cells, blast cells, cells secreting growth factors or related neurotrophic factors, or epithelial cells.

10. The nerve repair conduit of claim 1, wherein the nerve conduit further comprises a nerve graft.

11. The nerve repair conduit of claim 10, wherein the nerve graft is one of an allograft, an autograft, a xenograft, or a decellularized graft.

12. The nerve repair conduit of claim 10, wherein the nerve conduit substantially surrounds the nerve graft.

13. The nerve repair conduit of claim 10, wherein the nerve graft is one of an allograft, a xenograft, or a decellularized graft and the one or more drug reservoirs include at least one anti-rejection drug selected to prevent rejection of the graft.

14. The nerve repair conduit of claim 1, wherein the nerve repair conduit is configured for at least one of end-to-end, end-to-side, side-to-end, or side-to-side connection.

15. The nerve repair conduit of claim 1, wherein the polymeric body is comprised of at least one of poly(lactic-co-glycolic acid) (“

PLGA”

), spun silk, electrospun silk, polytetrafluoroethylene (“

PTFE”

), polydimethylsiloxane (“

PDMS”

), silicone, a salicylic acid-based polymer, a salicyl salicylic acid-based polymer, a difluorophenyl-salicylic acid-based polymer, collagen, fibrin, fibronectin, alginate, gelatin, keratin, thrombin, poly-glycolic acid, poly-(lactic acid), poly-caprolactone, poly-(L-lactic acid), poly(3-hydroxybutyric acid), poly((bis(hydroxyethyl) terephthalate-ethyl phosphoester/terephthaloyl chloride), poly(2-hydroxyethyl methacrylate) (“

PHEMA”

), a co-polymer of PHEMA and methyl methacrylate, or poly(acrylonitrile-co-methylacrylate).

16. The nerve repair conduit of claim 1, wherein the polymeric body has an interior diameter in a range of about 0.5 mm to about 2 cm, about 1 mm to about 1 cm, about 1 mm to about 5 mm, about 2 mm to about 4 mm, or about 2.5 mm to about 3 mm.

17. The nerve repair conduit of claim 1, wherein the outlet includes at least one of a semi-permeable membrane, nano-scale holes, micro-scale holes selectively formed in the polymeric body.

18. The nerve repair conduit of claim 17, wherein the semi-permeable membrane comprises one of polyethersulfone (“

PES”

) ethylene-vinyl acetate (“

EVA”

), or PLGA.

19. The nerve repair conduit of claim 17, wherein the nano-scale holes or micro-scale holes are selectively formed in the polymeric body are formed by laser ablation or track etch of the portions of the polymeric body.

20. The nerve repair conduit of claim 1, wherein the outlet is formed by selectively forming the polymeric body such that the at least one neurotrophic factor is able to diffuse into the interior lumen from the one or more drug reservoirs.

21. The nerve repair conduit of claim 1, wherein the outlet is formed by biodegradation of the polymeric body.

22. The nerve repair conduit of claim 1, wherein each of the separate reservoirs is associated with a different outlet, the polymeric body thereby including multiple different outlets for delivering multiple different drugs to the interior lumen at different locations in the interior lumen.

23. The nerve repair conduit of claim 1, wherein the excipient is one or more of polyvinyl alcohol (“

PVA”

), EVA, hyaluronic acid, chitosan, PEG, poly-PNIPA, polyepsilon caprolactone-co-lactide-polyethylene glycol, HEMA, or a hydrogel.

24. The nerve repair conduit of claim 1, wherein the at least one outlet is configured to deliver the at least one agent at a substantially constant rate for at least 24 hours, one week, two weeks, three weeks, or four weeks.

25. The nerve repair conduit of claim 24, wherein the duration of delivery of the at least one agent is a function of one or more of a volume of the one or more reservoirs, the excipient, number of outlets, outlet size, or diffusion rate of the at least one agent through the at least one outlet.

26. The nerve repair conduit of claim 1, wherein the nerve repair conduit is configured to deliver the at least one agent with substantially zero order kinetics for at least 2 weeks, three weeks, or four weeks.

27. The nerve repair conduit of claim 1, wherein the one or more drug reservoirs are contained in the polymeric body substantially at a site of nerve repair.

28. The nerve repair conduit of claim 27, wherein the polymeric body and the at least one outlet, are not connected to an ex vivo source of the agent.

29. The nerve repair conduit of claim 1, wherein the at least one agent is not integrated into the polymeric material used to form the conduit.

30. The nerve repair conduit of claim 1, wherein the one or more drug reservoirs disposed concentrically about the exterior surface of the polymeric body.

31. The nerve repair conduit of claim 1, wherein the at least one outlet is configured for delivering the at least one agent to the interior lumen of the polymeric body via diffusion.

32. The nerve repair conduit of claim 1, wherein the one or more drug reservoirs are arranged as a concentric cylinder that surrounds at least a portion of the polymeric body.

33. A nerve repair conduit, comprising:

a polymeric body having a proximal end, a distal end, an exterior surface and an interior surface defining an interior lumen, wherein the polymeric body is configured to be secured to a first portion of a nerve and a second portion of a nerve;

one or more drug reservoirs associated with the exterior surface of the polymeric body, wherein the one or more drug reservoirs contain at least one agent and optionally an excipient, wherein the one or more drug reservoirs further comprise one or more dividers forming separate reservoirs for separate agents within the one or more reservoirs, the one or more dividers being oriented orthogonal to a long axis of the nerve repair conduit to form the separate reservoirs at different longitudinal sections of the nerve repair conduit;

wherein the one or more drug reservoirs have an exterior surface abutting the exterior surface of the polymeric body; and

at least one outlet formed between the one or more drug reservoirs, the exterior surface of the polymeric body, and the interior surface of the polymeric body so as to enable delivery of the at least one agent from the separate reservoirs through the polymeric body to the interior lumen of the polymeric body without requiring degradation of the polymeric body for release of the at least one agent.

34. A nerve repair conduit, comprising:

a polymeric body having a proximal end, a distal end, an exterior surface and an interior surface defining an interior lumen, wherein the polymeric body is configured to be secured to a first portion of a nerve and a second portion of a nerve;

one or more drug reservoirs disposed concentrically around the exterior surface of the polymeric body, wherein the one or more drug reservoirs contain at least one agent and optionally an excipient;

wherein the one or more drug reservoirs further comprise one or more dividers forming separate reservoirs for separate agents within the one or more reservoirs, the one or more dividers being oriented orthogonal to a long axis of the nerve repair conduit to form the separate reservoirs at different longitudinal sections of the nerve repair conduit; and

at least one outlet formed between the one or more drug reservoirs, the exterior surface of the polymeric body, and the interior surface of the polymeric body so as to enable delivery of the at least one agent from the separate reservoirs through the polymeric body to the interior lumen of the polymeric body without requiring degradation of the polymeric body for release of the at least one agent.

35. A nerve repair conduit, comprising:

a polymeric body having a proximal end, a distal end, an exterior surface and an interior surface defining an interior lumen, wherein the polymeric body is configured to be secured to a first portion of a nerve and a second portion of a nerve, the first portion or the second portion of the nerve including one or more of an uninjured but inflamed nerve, an injured but intact nerve, a partially transected nerve, or a transected nerve;

one or more drug reservoirs associated with the exterior surface of the polymeric body, wherein the one or more drug reservoirs contain at least one agent and optionally an excipient, wherein the one or more drug reservoirs further comprise one or more dividers forming separate reservoirs for separate agents within the one or more reservoirs, the one or more dividers being oriented orthogonal to a long axis of the nerve repair conduit to form the separate reservoirs at different longitudinal sections of the nerve repair conduit;

the one or more drug reservoirs being disposed concentrically about the exterior surface of the polymeric body, the at least one agent including a neurotrophic factor selected to enhance the rate of nerve regeneration;

at least one outlet formed between the one or more drug reservoirs, and the interior surface of the polymeric body, the at least one outlet including micro-scale holes for delivering the at least one agent from the separate reservoirs through the polymeric body to the interior lumen of the polymeric body via diffusion through the micro-scale holes and without requiring degradation of the polymeric body for release of the at least one agent; and

a substantially tubular member disposed around the exterior surface of the polymeric body, wherein the one or more drug reservoirs are formed in a space between the exterior surface of the polymeric body and the substantially tubular member,

wherein the nerve repair conduit is configured to deliver the at least one agent at a constant rate of diffusion over a period of time of at least 3 days.